ARID1A deficiency activates OSM-STAT3 axis in endometrial cancer, creating vulnerability to JAK/STAT3 inhibition.

Although the results did not reach statistical significance—primarily due to the limited sample size—a clear trend emerged: higher ARID1A expression is associated with improved patient survival, whereas elevated OSM levels correlate with poorer survival outcomes (Fig. 7 J).

also in 111,027 other papers

Our results show a clear trend of hypersensitivity of ARID1A-mutant cells to JAK/STAT3 inhibitors in endometrial cancer as well as other type of cancer cells (Fig. 1 L-N).

also in 19,460 other papers

The results showed a trend of higher expression of OSM than that of ARID1A in the patients (Fig. 7 G-H).

also in 53,322 other papers